ERBB2 and breast cancer: In combination with the fluoropyrimidine capecitabine, lapatinib is more efficient than capecitabine alone in women with ErbB2-positive advanced breast cancer that has progressed after treatment with anthracyclines, taxanes, and trastuzumab [23, 24].